A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Centinel Spine Announces First Commercial Use of prodisc® C SK Cervical Total Disc Replacement Product

Centinel Spine®, LLC, (“the Company”) a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the first implantation of its prodisc® C SK Cervical Total Disc Replacement (TDR) product. In July, the Company received U.S. Food and Drug Administration approval for 1-level indications for prodisc C Vivo, prodisc C SK, and prodisc C Nova. The prodisc C SK system is the second of the three new products to be released with the Company recently announcing the 100th completed procedure with its prodisc C Vivo TDR product.

Along with the currently available prodisc C implant, Centinel Spine has the broadest offering of cervical TDR solutions in the world to address individual patient anatomy and meet surgeon preference needs.

“In spine care, each patient’s circumstances are different, so it is critical to provide surgeons with the ability to address each patient’s unique needs,” said Centinel Spine CEO Steve Murray. “With the release of both the prodisc C Vivo and prodisc C SK devices, we have expanded the options available to surgeons to allow for better matching of the disc to the patient. While these two new product releases have been conducted on a limited scale, we have already seen a strong positive response from surgeon partners related to the potential patient benefits.”

The prodisc C SK device features a flat endplate design for optimized implant positioning that allows surgeons to address individual patient anatomy—and a low-profile central keel that provides immediate fixation and enables a streamlined keel preparation technique. Similar to all prodisc products, the prodisc C SK device incorporates prodisc CORE technology, the basis behind the predictable clinical outcomes of the prodisc platform after 30 years and over 225,000 implantations worldwide.*

According to orthopedic spine surgeon Ehsan Jazini, MD, from the Virginia Spine Institute in Reston, Virginia, “I am proud to be the first surgeon to use this innovative technology in the DC metro region. As a pioneer working to make disc replacement surgery ultra-customized for each patient, the prodisc C SK and prodisc C Vivo devices provide me the versatility to match the disc to the patient’s anatomy. With this advanced proven technology, we can best gain motion preservation and stability as appropriate for each cervical surgery.”

Orthopedic spine surgeon Jason Tinley, MD, founder of the DFW Center for Spinal Disorders in Dallas-Fort Worth, Texas, agrees, noting, “With prodisc C SK now FDA-approved along with prodisc C Vivo and the original prodisc C, I have the intra-operative modularity to change implant characteristics based on patient morphology. While an MRI or X-ray may appear to favor the need for a flat endplate and keels versus a superior dome shape with spikes, once your carpentry is performed, I’ve found that it’s not uncommon that the alternative option may actually offer better stability and endplate conformity upon trialing.”

* Data on file

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy